

Orthopediatrics Corp. (KIDS)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001425450

Orthopediatrics Corp.

KIDS; healthcare

Grade	A A B C D E strongest fifth of 371 graded peers percentile 11.9; sampling error 2.5 points; lower is stronger	
Rank	45 of 371	
Profitability	B	percentile 35.7
Solvency	B	percentile 29.5
Growth and financing	B	percentile 36.3
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025	
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$120M to \$591M assets total assets \$508.6M	
Standard universe	inside revenue above \$1M and assets above \$10M	
Warnings	none active	
Inputs computable	9 of 14	
Graded from	filings received through Mar 4, 2026 219 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026	
Last close	\$21.79 2026-10-08; market equity \$568.9M	
Price used in grade	None	



A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Sep 21, 2023, B from Oct 21, 2023, A/B from Nov 21, 2023, A from Apr 21, 2024

Letter at every rescanscan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words


opening of Item 1 of the 10-K received Mar 4, 2026

OrthoPediatics Corp. (the "Company") is a Delaware corporation, headquartered in Warsaw, Indiana, and organized in November 2007. The Company's Common Stock is traded on the Nasdaq Global Market under the symbol KIDS. OrthoPediatics Corp. is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. Initially organized as an Indiana limited liability company on

The fourteen inputs*lower percentile is stronger; equal-weighted sleeves*

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 35.7						
Gross profitability		33.9%	32.2%	41.0	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(7.1%)	(6.6%)	53.5	811	2025-12-31
Gross margin stability, five years		0.9 pts	2.8 pts	12.8	243	2025-12-31
Solvency, sleeve percentile 29.5						
Twelve-month failure probability		0.04%	0.07%	29.1	248	2026-06-30
Altman Z double-prime		2.67	(0.31)	26.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31
Current ratio		5.55x	2.96x	32.8	839	2025-12-31
Growth and financing, sleeve percentile 36.3						
Revenue growth, three-year compound		24.6%	10.0%	26.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		5.9%	2.1%	39.0	704	2025-12-31
Net share issuance, one year		4.1%	2.5%	43.0	634	2026-02-28

Among 371 peers*healthcare; letters are fifths of this list*



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
40	TG Therapeutics, Inc. (TGTX)	10.5	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	
43	PRO DEX Inc. (PDEX)	11.4	A	
44	Sanara MedTech Inc. (SMTI)	11.6	A	
45	Orthopediatrics Corp. (KIDS) <	11.9	A	
46	Idexx Laboratories Inc. (IDXX)	12.2	A	
47	Procept BioRobotics Corp. (PRCT)	12.4	A	fortress
				balance sheet
48	Natera, Inc. (NTRA)	12.7	A	fortress
				balance sheet
49	Utah Medical Products Inc. (UTMD)	13.0	A	fortress
				balance sheet
50	Insulet Corp. (PODD)	13.2	A	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	25.8%	8.0%	62
Distance from 52-week high	(17.9%)	(31.4%)	68
EBIT to enterprise value	(6.0%)	(1.5%)	38
Free cash flow yield	(2.8%)	(1.0%)	45
Book value to price	0.60	0.28	75
Sales to price	0.42	0.31	60
Composite equity issuance, five years	28.4%	20.3%	56
Relative strength against the sector, log excess return	0.02	(0.14)	62

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$17.0M
Operating cash flow, four quarters	\$7.4M
Months of runway	not finite

Days since last periodic filing

65 (10-Q received Aug 5, 2026)

Median daily dollar volume, 63 sessions

\$4.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$172.7M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
2	assets	us-gaap:Assets	\$508.6M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
3	operating income	us-gaap:OperatingIncomeLoss	-\$39.2M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$19.2M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$460,000	2025-12-31	2026-03-04	10-K	0001425450-26-000013
6	total debt	us-gaap:LongTermDebt	\$106.0M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
7	book equity	us-gaap:StockholdersEquity	\$346.6M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$19.6M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
9	total debt	us-gaap:LongTermDebt	\$77.5M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
10	book equity	us-gaap:StockholdersEquity	\$354.6M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$43.8M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
12	net income	us-gaap:NetIncomeLoss	-\$39.6M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$4.9M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
14	assets	us-gaap:Assets	\$473.2M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$236.3M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
16	gross profit	us-gaap:GrossProfit	\$148.6M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$204.7M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
18	gross profit	us-gaap:GrossProfit	\$111.3M	2023-12-31	2026-03-04	10-K	0001425450-26-000013
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$148.7M	2023-12-31	2026-03-04	10-K	0001425450-26-000013
20	gross profit	us-gaap:GrossProfit	\$90.7M	2022-12-31	2025-03-05	10-K	0001425450-25-000015
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$122.3M	2022-12-31	2025-03-05	10-K	0001425450-25-000015
22	gross profit	us-gaap:GrossProfit	\$73.4M	2021-12-31	2024-03-08	10-K	0001425450-24-000013
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$98.0M	2021-12-31	2024-03-08	10-K	0001425450-24-000013
24	current assets	us-gaap:AssetsCurrent	\$256.4M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
25	current liabilities	us-gaap:LiabilitiesCurrent	\$46.2M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$275.2M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
27	liabilities	us-gaap:Liabilities	\$162.0M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$21.1M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
29	operating income	us-gaap:OperatingIncomeLoss	-\$26.8M	2020-12-31	2023-03-01	10-K	0001425450-23-000024
30	interest expense	us-gaap:InterestExpense	\$3.4M	2020-12-31	2021-03-11	10-K	0001425450-21-000047
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$11.1M	2025-12-31	2026-03-04	10-K	0001425450-26-000013
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.0M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14.3M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.0M	2023-12-31	2026-03-04	10-K	0001425450-26-000013
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$16.9M	2023-12-31	2026-03-04	10-K	0001425450-26-000013
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$21.8M	2022-12-31	2025-03-05	10-K	0001425450-25-000015
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$10.0M	2022-12-31	2025-03-05	10-K	0001425450-25-000015
38	current assets	us-gaap:AssetsCurrent	\$237.2M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
39	current liabilities	us-gaap:LiabilitiesCurrent	\$34.0M	2024-12-31	2026-03-04	10-K	0001425450-26-000013
40	assets	us-gaap:Assets	\$438.7M	2023-12-31	2025-03-05	10-K	0001425450-25-000015
41	assets	us-gaap:Assets	\$427.7M	2022-12-31	2024-03-08	10-K	0001425450-24-000013
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,278,787	2026-02-28	2026-03-04	10-K	0001425450-26-000013
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,286,590	2025-03-01	2025-03-05	10-K	0001425450-25-000015